We are pursuing drugs
For many diseases, biology reveals the most compelling drug targets, yet drug discovery struggles to reach them. We're unlocking these undruggable targets through chemical biology and pharmacology enabled by covalent ligand discovery across all nucleophilic amino acids.
Targets of Current Drugs
proteins with well-defined
binding pockets
kinases and other enzymes
GPCRs | hormone receptors
20%
80%
Undruggable Targets
proteins without well-defined
binding pockets
intrinsically disordered proteins
scaffolding proteins | transcription factors
proteins with challenging
binding pockets
paralogs | protein-protein interfaces
Targets of Current Drugs
proteins with well-defined
binding pockets
kinases and other enzymes
GPCRs | hormone receptors
Undruggable Targets
proteins without well-defined
binding pockets
intrinsically disordered proteins
scaffolding proteins | transcription factors
proteins with challenging
binding pockets
paralogs | protein-protein interfaces
Our Science
Biology maps targets CODON provides ligands Chemical Biology powers drug discovery
Our approach
Chemical biology is at our core. It's the glue connecting chemistry and biology to reveal how to drug the hardest targets.
Origins
Biology maps the targets. We follow that signal even when conventional approaches fall short.
The foothold
Every breakthrough starts with a foothold. Covalent chemistry lets us engage and unlock undruggable targets.
Our CODON library includes >12,000 covalent ligands, designed with low promiscuity and tuned to access transient cryptic pockets.
Fit to target
There is no playbook for undruggable targets.
Our approach is flexible by necessity.
We combine protein structure and computation to evolve covalent hits into high-quality leads, aligning modality with biology.
Pharmacology is tailored to each target, with integrated PK/PD modeling guiding optimization from leads to drug candidates.
The CODON platform delivers progressable covalent hits for undruggable targets
